Merrimack Pharmaceut (MACK) 5.82 $MACK Merrimack (MACK):

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merrimack Pharmaceut (MACK) 5.82 $MACK

Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Merrimack (MACK) is scheduled to report second-quarter 2016 results on Aug 4.
MACK: 5.82 (+0.02), IRWD: 13.94 (-0.19), LLY: 83.18 (+0.29), EXEL: 9.27 (+0.09)

Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 5:45PM CDT
Celgene's (CELG) Revlimid gained label expansion in the EU; it can now be used for the treatment of adults with relapsed or refractory mantle cell lymphoma.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), CELG: 114.69 (+2.50)

ZIOPHARM (ZIOP) Stock Down on Patient Death in Phase I
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
ZIOPHARM (ZIOP) announced the death of a patient in a phase I study on Ad-RTS-hIL-12 in the treatment of recurrent or progressive GBM or grade III malignant glioma.
MACK: 5.82 (+0.02), ZIOP: 5.06 (+0.20), INVA: 13.04 (+0.17), XON: 27.38 (+2.05)

Gilead's HCV Drug Epclusa Gets Regulatory Nod in Canada
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 9:36AM CDT
Gilead (GILD) received a Notice of Compliance from Health Canada for Epclusa for the treatment of adults with genotype 1-6 chronic HCV infection.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch)

Ultragenyx (RARE) Reports Positive Phase III rhGUS Data
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 8:51AM CDT
Ultragenyx (RARE) announced top-line data from a pivotal phase III study on rhGUS for the treatment of mucopolysaccharidosis 7.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), RARE: 63.53 (+0.25), PFE: 37.31 (+0.42)

Bayer Expands Drug Discovery Collaboration with X-Chem
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 3:06PM CDT
Bayer (BAYRY) inked an expanded global drug discovery deal with X-Chem, Inc. across multiple therapeutic areas and target classes.
MACK: 5.82 (+0.02), FCSC: 1.02 (-0.07), BMY: 76.19 (+1.38)

BioDelivery Sciences (BDSI) Catches Eye: Stock Rises 12%
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:15AM CDT
BioDelivery Sciences International, Inc.(BDSI) shares rose 12% on the day.
MACK: 5.82 (+0.02), BDSI: 2.41 (-0.14)

CytRx (CYTR) Stock Falls on Unfavorable Aldoxorubicin Data
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 6:07AM CDT
CytRx (CYTR) announced unfavorable initial results from a phase III study on aldoxorubicin in patients with relapsed or refractory soft tissue sarcomas.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), GWPH: 96.11 (+1.79), CYTR: 0.60 (-0.05)

Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold
Arpita Dutt - Zacks Investment Research - Wed Jul 13, 4:46AM CDT
Juno's (JUNO) shares were up in after-market hours following the lifting of the clincal hold on the company's pivotal ROCKET study.
MACK: 5.82 (+0.02), BLUE: 56.30 (-0.88), KITE: 57.03 (+0.40), JUNO: 30.86 (-0.07)

Merrimack Stock Up on Fast Track Status for Seribantumab
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:22PM CDT
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), GWPH: 96.11 (+1.79), UTHR: 125.08 (+4.07)

Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 5.82 (+0.02), ALNY: 71.80 (+3.72), GERN: 2.71 (+0.03), CYTR: 0.60 (-0.05)

The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 5.82 (+0.02), BIIB: 301.83 (+11.90), IDRA: 1.67 (-0.05), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 5.82 (+0.02), BIIB: 301.83 (+11.90), IDRA: 1.67 (-0.05), RTRX: 18.17 (+0.24), LGND: 138.53 (+3.65), ACOR: 25.13 (-0.15)

Merrimack Announces Positive Data on Oncology Candidate
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 3:57PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) announced results from the phase I study on pipeline candidate, MM-151.
MACK: 5.82 (+0.02), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), PFE: 37.31 (+0.42)

Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in Multiple Solid Tumor Types, Including Colorectal Cancer
PR Newswire - Mon Jun 06, 6:30AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced results from the final analysis of the Phase 1 study of MM-151, a novel investigational oligoclonal epidermal growth factor receptor (EGFR) inhibitor, in patients with refractory solid tumors. These results were presented at a Poster Discussion Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
MACK: 5.82 (+0.02)

Merrimack/Baxalta Start Study on Colorectal Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri May 20, 1:37PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) and Baxalta Incorporated (BXLT) announced that the companies have initiated a phase I clinical study on pipeline candidate, MM-151.
MACK: 5.82 (+0.02), ABT: 45.29 (+0.54), PFE: 37.31 (+0.42), BXLT: 46.02 (-0.18)

Merrimack Announces a Leading-edge Biomarker-Selected, Multi-Arm Basket Trial that Matches Patients with Most Appropriate Combination Regimens
PR Newswire - Thu May 19, 6:05AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced today the initiation of a biomarker-selected, multi-arm Phase 1 clinical study in metastatic colorectal, non-small cell lung, and head and neck cancers. Merrimack's first-of-its-kind basket study will use a combination of genetic and nongenetic biomarkers to match patients to appropriate novel combinations of investigational drug regimens based on their cancer's molecular signature. This approach is expected to enable more than 95 percent of eligible patients to qualify for enrollment to one of the investigational arms of the study. Merrimack utilized its systems biology approach to identify the biomarkers and selection criteria of the study.
MACK: 5.82 (+0.02)

Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer
PR Newswire - Thu May 19, 6:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced the initiation of a Phase 1 clinical study of Merrimack's oligoclonal EGFR (epidermal growth factor receptor) inhibitor, MM-151, in combination with ONIVYDE® (irinotecan liposome injection) plus fluorouracil (5-FU) and leucovorin in patients with RAS wild-type metastatic colorectal cancer. Data from a prior Phase 1 study of MM-151 supports further clinical evaluation of the investigational therapy in patients with metastatic colorectal cancer. The initiation of this study advances the development path for ONIVYDE.
MACK: 5.82 (+0.02), BXLT: 46.02 (-0.18)

Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting
PR Newswire - Wed May 18, 4:10PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present on its extensive oncology pipeline at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016 at McCormick Place, Chicago, Illinois. Final results from a Phase 1 study evaluating the safety, pharmacology and initial efficacy of MM-151 will be presented in a Poster Discussion Session. Merrimack will also present on the results from its Phase 3 NAPOLI-1 study of ONIVYDE®, as well as on multiple therapeutic candidates from its antibody engineering and antibody-directed nanotherapeutic (ADN) technology platforms in six poster sessions.
MACK: 5.82 (+0.02)

Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series
PR Newswire - Tue May 17, 3:05PM CDT
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today presented an expanded analysis of its Phase 2 study of seribantumab (MM-121) in combination with exemestane in HER2-negative, hormone receptor positive metastatic breast cancer. Top line results from this study were announced in 2014. The final analysis, as well as a poster on Merrimack's investigational companion diagnostic for seribantumab, were presented this week at the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, in Miami, Florida.
MACK: 5.82 (+0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 152

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 157

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 84

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 227

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 111

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 182

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 26

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 135

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Rush to ExoraPad: The Rise of $EXP Tokens Explained

Updated Category News Views 219

Investors Flock to ExoraPad as the $EXP Token Presale Surges As the digital currency landscape evolves, many investors are seeking the next big opportunity. ExoraPad has emerged as a focal point in this space, particularly for those involved with XRP. The ongoing presale for the $EXP token has garnered immense attention, attracting numerous investors eager to secure their...

Continue Reading
Key Insights on DFDS A/S Share Transactions Involving Managers

Updated Category News Views 251

Recent Share Transactions by DFDS A/S Leadership On February 25, a significant transaction was recorded involving Claus V. Hemmingsen, the Chair of the Board of Directors for DFDS A/S, who purchased 5,000 shares of the company. This action showcases the confidence of the company’s leadership in its growth trajectory and operational strategy. Regulatory Obligations Under...

Continue Reading
First Guaranty Bancshares Reaches New Stock Milestone

Updated Category News Views 253

First Guaranty Bancshares Achieves New Milestone First Guaranty Bancshares Inc (NASDAQ: FGBI) has recently achieved a notable milestone, with its stock hitting a new 52-week high of $13.38. This impressive leap highlights a phase of robust growth for the company, reflected in the rising stock price that has been buoyed by favorable market sentiments. Over the past year,...

Continue Reading
Pho Hoa & Jazen Tea Expands Southeast with New Location

Updated Category News Views 314

Pho Hoa & Jazen Tea Expands into the Southeast Pho Hoa & Jazen Tea is excited to announce the grand opening of a new restaurant in Marietta, marking an important milestone in the brand's expansion strategy. With over 40 years dedicated to perfecting pho noodle soup, the company is eager to bring its incredible Vietnamese culinary experience to new customers. Exciting New...

Continue Reading
IDT Corporation's Commitment to Shareholders with New Dividend

Updated Category News Views 74

IDT Corporation Announces Quarterly Dividend for Shareholders IDT Corporation (NYSE: IDT), a key player in communications and payment services, has recently made waves by declaring a quarterly cash dividend of $0.05 per share. This news was shared through a regulatory filing, illustrating the company's ongoing commitment to providing value to its shareholders. Details on...

Continue Reading